Flexion Therapeutics Inc (NASDAQ:FLXN) – Analysts at Cantor Fitzgerald decreased their FY2017 EPS estimates for Flexion Therapeutics in a research note issued on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst C. Russo now anticipates that the specialty pharmaceutical company will post earnings per share of ($4.69) for the year, down from their prior forecast of ($3.99). Cantor Fitzgerald has a “Overweight” rating and a $34.00 price objective on the stock.
A number of other analysts also recently issued reports on the company. Royal Bank of Canada set a $44.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Sunday, March 26th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Flexion Therapeutics in a research note on Saturday, March 25th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 14th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Flexion Therapeutics in a research note on Saturday, March 11th. Finally, BMO Capital Markets reaffirmed a “positive” rating and issued a $33.00 price objective on shares of Flexion Therapeutics in a research note on Tuesday, February 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $28.68.
Flexion Therapeutics (NASDAQ:FLXN) traded down 2.19% during midday trading on Thursday, reaching $26.37. 320,694 shares of the company’s stock traded hands. Flexion Therapeutics has a one year low of $8.16 and a one year high of $29.41. The stock’s 50 day moving average price is $24.28 and its 200-day moving average price is $20.44. The stock’s market cap is $836.75 million.
Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Thursday, March 9th. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by $0.07.
A number of institutional investors have recently made changes to their positions in FLXN. Keybank National Association OH increased its position in shares of Flexion Therapeutics by 0.7% in the fourth quarter. Keybank National Association OH now owns 10,357 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 67 shares during the period. SECOR Capital Advisors LP acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $214,000. Stoneridge Investment Partners LLC acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $271,000. Jennison Associates LLC acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $402,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $620,000. 62.25% of the stock is currently owned by institutional investors.
In other Flexion Therapeutics news, CFO Frederick W. Driscoll sold 3,000 shares of the company’s stock in a transaction on Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total value of $69,000.00. Following the transaction, the chief financial officer now owns 10,777 shares of the company’s stock, valued at approximately $247,871. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Neil Bodick sold 5,000 shares of the company’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $28.23, for a total value of $141,150.00. Following the completion of the transaction, the insider now directly owns 46,137 shares in the company, valued at approximately $1,302,447.51. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,000 shares of company stock worth $407,950. Corporate insiders own 18.00% of the company’s stock.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.